Keith Tapper
Stock Analyst at BMO Capital
(2.28)
# 2,773
Out of 4,984 analysts
6
Total ratings
66.67%
Success rate
6.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Keith Tapper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NGNE Neurogene | Maintains: Outperform | $45 → $16 | $17.71 | -9.66% | 4 | Apr 14, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Outperform | $5 | $2.90 | +72.41% | 1 | Jun 27, 2024 | |
| ACAD ACADIA Pharmaceuticals | Initiates: Outperform | $31 | $24.20 | +28.10% | 1 | Jun 27, 2024 |
Neurogene
Apr 14, 2025
Maintains: Outperform
Price Target: $45 → $16
Current: $17.71
Upside: -9.66%
Taysha Gene Therapies
Jun 27, 2024
Initiates: Outperform
Price Target: $5
Current: $2.90
Upside: +72.41%
ACADIA Pharmaceuticals
Jun 27, 2024
Initiates: Outperform
Price Target: $31
Current: $24.20
Upside: +28.10%